Sangamo Therapeutics, Inc (SGMO) — 8-K Filings

8-K Filings (19)

• Sangamo Therapeutics Faces Delisting Notice — Oct 29, 2025 Risk: high
  Sangamo Therapeutics, Inc. filed an 8-K on October 29, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, former
• Sangamo Therapeutics Reports Officer and Director Changes — Sep 30, 2025 Risk: medium
  Sangamo Therapeutics, Inc. filed an 8-K on September 30, 2025, reporting changes effective September 24, 2025. The filing pertains to the departure of directors
• Sangamo Therapeutics Reports Officer and Director Changes — Sep 11, 2025 Risk: medium
  Sangamo Therapeutics, Inc. filed an 8-K on September 11, 2025, reporting changes effective September 9, 2025. The filing pertains to the departure of directors
• Sangamo Therapeutics Files 8-K — Sep 4, 2025 Risk: medium
  Sangamo Therapeutics, Inc. filed an 8-K on September 4, 2025, to report other events. The filing does not contain specific details about the nature of these eve
• Sangamo Therapeutics Files 8-K Report — Jun 24, 2025 Risk: low
  On June 24, 2025, Sangamo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transactions or fina
• Sangamo Therapeutics Announces Board Changes and Shareholder Votes — Jun 16, 2025 Risk: medium
  Sangamo Therapeutics, Inc. announced on June 12, 2025, a series of significant corporate actions. These include the departure of two directors, the election of
• Sangamo Therapeutics Files 8-K — May 13, 2025 Risk: low
  On May 12, 2025, Sangamo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specif
• Sangamo Therapeutics Faces Delisting Concerns — May 6, 2025 Risk: high
  Sangamo Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of April 3
• Sangamo Therapeutics Relocates Principal Executive Offices — Feb 6, 2025 Risk: low
  On February 6, 2025, Sangamo Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 501 Canal Blv
• Sangamo Therapeutics Terminates Material Definitive Agreement — Dec 30, 2024 Risk: medium
  Sangamo Therapeutics, Inc. announced on December 22, 2024, the termination of a material definitive agreement. The company, headquartered in Richmond, Californi
• Kite to Acquire Sangamo Therapeutics for $3.4B — Dec 10, 2024 Risk: medium
  Sangamo Therapeutics, Inc. announced on December 9, 2024, that it has entered into a definitive agreement to be acquired by Kite, a Gilead Company. The transact
• Sangamo Therapeutics Files 8-K — Oct 4, 2024 Risk: low
  On October 4, 2024, Sangamo Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material information th
• Sangamo Therapeutics Files 8-K — Aug 6, 2024 Risk: low
  Sangamo Therapeutics, Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition, as well as financial statements and e
• Kite to Acquire Sangamo Therapeutics for $3.4B — Jul 24, 2024 Risk: medium
  Sangamo Therapeutics, Inc. announced on July 24, 2024, that it has entered into a definitive agreement to be acquired by Kite, a Gilead Company. The transaction
• Sangamo Therapeutics Announces Corporate Changes — Jun 5, 2024 Risk: medium
  Sangamo Therapeutics, Inc. announced on June 4, 2024, a series of corporate actions including the election of new directors, changes in officer roles, and the a
• Sangamo Therapeutics Faces Nasdaq Delisting Warning — Apr 30, 2024 Risk: medium
  Sangamo Therapeutics, Inc. announced on April 24, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules due
• Sangamo Therapeutics Closes $55.2M Public Offering — Mar 25, 2024 Risk: medium
  On March 21, 2024, Sangamo Therapeutics, Inc. filed an 8-K report to announce the closing of its previously announced underwritten public offering. The company
• Sangamo Therapeutics Files 8-K for 'Other Event' on Feb 5 — Feb 6, 2024
  Sangamo Therapeutics, Inc. (SGMO) filed an 8-K on February 6, 2024, reporting an 'Other Event' that occurred on February 5, 2024. This filing indicates a routin
• Sangamo Therapeutics Updates Principal Executive Office Address — Jan 19, 2024
  Sangamo Therapeutics, Inc. (SGMO) filed an 8-K on January 19, 2024, to report a change in its principal executive offices from 7000 Marina Blvd., Brisbane, Cali

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX